Lewis Weinstein, MD
Ophthalmology · Commack, NYNPI 1407879638
Payments from drug & device makers
Across 19 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$126
- Tarsus Pharmaceuticals, Inc.$74
- Bausch & Lomb Americas Inc.$71
- Sun Pharmaceutical Industries Inc.$43
- Harrow Eye, LLC$32
- Alcon$22
- plus $52 from 3 others
What the payments were for
- Food & beverage$40196%
- Education$184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 5 | $126 |
| Tarsus Pharmaceuticals, Inc. | 3 | $74 |
| Bausch & Lomb Americas Inc. | 4 | $71 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Harrow Eye, LLC | 1 | $32 |
| Alcon | 1 | $22 |
| Thea Pharma Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
How this compares
$419 in reported general payments places this provider in the 30th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 32 | $32,736 |
| XiidraLifitegrast | 18 | $15,739 |
| Cyclosporine | 11 | $7,133 |
| Brimonidine Tartrate | 29 | $2,767 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 55 | $2,308 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 61 | $1,397 |
| Latanoprost | 122 | $1,310 |
| Dorzolamide Hcl | 16 | $335 |
| Prednisolone Acetate | 11 | $293 |
| Timolol Maleate | 26 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $16 | $32,73632 claims |
| Bausch & Lomb Americas Inc.Xiidra | $71 | $15,73918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Commack
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.